



#### ASX Release

11 October 2018

**ZELDA THERAPEUTICS LIMITED**  
ACN 103 782 378

Level 26  
140 St Georges Terrace,  
Perth Western Australia 6000  
Tel: +61 8 6558 0886  
Fax: +61 8 6316 3337  
enquiries@zeldatherapeutics.com  
www.zeldatherapeutics.com

#### Contacts:

##### Zelda Therapeutics

Dr Richard Hopkins  
Managing Director  
+61 405 656 868  
rhopkins@zeldatherapeutics.com

Monsoon Communications  
Rudi Michelson  
+61 3 9620 3333  
rudim@monsoon.com

##### Directors

Dr Richard Hopkins  
Mr Harry Karelis  
Dr Stewart Washer  
Ms Mara Gordon  
Mr Jason Peterson

##### Tickers:

Australia (ASX): ZLD  
USA (OTCQB): ZLDAF

**Ordinary Shares:**  
755,341,934

**Options:**  
49,000,000

1,500,000 (\$0.04 – 6/2/2020)  
\*4,500,000 (\$0.04 – 6/2/2020)  
1,000,000 (\$0.125 – 22/8/2021)  
\*2,000,000 (\$0.125 – 22/8/2021)  
40,000,000 (\$0.03125 – 17/11/2021)  
\* subject to vesting conditions

## Zelda focuses clinical trial activity

- **Zelda's clinical trial programmes progressing well**
- **Zelda and Fundación Daya have agreed to end their clinical trial collaboration in Chile**
- **Resources focussed on the largest global markets for medicinal cannabis**

**Zelda Therapeutics Limited (ASX: ZLD, OTCQB: ZLDAF):** has completed a strategic review of its clinical trial operations and decided to prioritise its current clinical trial activities in the United States of America (USA) and Australia and to cease clinical operations in Chile. Furthermore, the company's eczema programme will be de-prioritised for the time being.

This will ensure Zelda's resources are focussed on generating clinical data that will best facilitate access to the largest global markets for medicinal cannabis.

Zelda is currently undertaking clinical trials in autism and insomnia in the USA and Australia. The Company recently announced the first patient being successfully dosed for its insomnia trial and that it has commenced recruitment for its observational trial for autism in the USA.

In addition, the company expects to be announcing new clinical initiatives and this focus will allow Zelda to take-on these new programmes.

#### **Dr Richard Hopkins, Zelda's Managing Director, said:**

*"Following the recent strategic review, the board decided to cease clinical operations in Chile to concentrate on our clinical trial activities in the US and Australia.*

*Successful outcomes to clinical studies undertaken in these countries will strengthen our commercialisation position in all major global markets, including Chile. Companies evaluating license deals usually put greater weight on US and Australian-based clinical trials so it makes sense to focus on these markets."*

**Tim Slate**  
**Company Secretary**

## **About Zelda Therapeutics ([www.zeldatherapeutics.com](http://www.zeldatherapeutics.com))**

Zelda Therapeutics Ltd is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-armed strategy comprising:

- A **human clinical trial programme** focused on insomnia and autism with activities in Australia and the USA.
- A **pre-clinical research programme** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

It has partnered with the world's leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer and cognitive decline.